Research by Condition
Research by Condition
The following index consolidates clinical findings from the BEMER Medical Expert Center Research Compendium — a 534-page compilation of studies, multi-centre data, and clinical case series accumulated between 1999 and 2013. The compendium spans 15 medical specialties and documents outcomes across more than 3,000 patients in clinical settings across Germany, Austria, Switzerland, Hungary, Czech Republic, and Sweden. This is the foundational research base that supported BEMER's CE Class IIa medical device classification and established its clinical profile over the first decade of use. Research and clinical application have continued in the years since.
Evidence levels
Randomised, controlled, blinded trial (highest evidence level)
Observational data across multiple independent clinical facilities
Comparison group; not fully randomised
Multiple documented cases with consistent findings
Single patient with detailed documentation
Musculoskeletal and Pain
Acute musculoskeletal pain
Multi-centre (220 facilities) · n=2,000+ · 2–4 weeks
90–96%
Chronic back pain / spine syndromes
Multi-centre · n=243 · 6 weeks
89%
Sciatica / lumbago
Multi-centre · n=46 · 4 weeks
91%
Joint pain / arthralgia
Multi-centre · n=47 · 4 weeks
92%
Arthrosis / arthritis
Multi-centre · n=236 · 6 weeks
83%
Shoulder impingement
Multi-centre · n=46 · 6 weeks
93%
Muscle tension
Multi-centre · n=48 · 5 weeks
87% symptom-free
Rheumatic symptoms
Multi-centre · n=48 · 6 weeks
94%
Trauma consequences
Multi-centre · n=48 · 2 weeks
100%
Neurosurgical spine (cervical + lumbar)
3-year observational · n=115 · Variable
~92%
Notable: Accident injuries (bruising, distortions, swelling) showed the highest acute response rates in the Schönfeld general practice study — over 95% positive.
Fracture and Bone Healing
Fracture healing
Multi-centre · n=22 · 5 weeks
100%
Sacral H-fracture (manifest osteoporosis)
Controlled case report · n=1 · 7 weeks
Near-complete consolidation
Osteoporosis pain
Multi-centre · n=30 · 6 weeks
90%
Notable: The sacral H-fracture case provides a controlled natural comparison — 7+ months of standard orthopaedic treatment without consolidation, followed by 7 weeks of BEMER with near-complete consolidation confirmed on CT imaging. Surgery was avoided.
Wound Healing and Dermatology
Wound healing disorders
Multi-centre · n=29 · 4 weeks
93%
Chronic venous leg ulcers
Case series · n=3 · 30 sessions–9 months
100% (complete healing)
Neuropathic diabetic foot ulcer
Case report · n=1 · 3 months
Complete wound closure
Arterial ulcus cruris
Case report · n=1 · 6+ weeks
Significant improvement (partial)
Post-surgical facial trauma
Case report · n=1 · 7 days
Healing in 7 days vs 2–3 week average
Diabetic polyneuropathy (microcirculation)
Controlled study (Klopp) · n=Group · 60 days
Significant improvement day 8–10
Bisphosphonate jaw osteonecrosis (ONJ)
Clinical series · n=Not specified · Post-surgical
Improved healing; relapse prevented
Neurological and Neurosurgical
MS-related fatigue
RCT (blinded) · n=37 · 12 weeks
MFIS p=0.024; FSS p=0.016
Multiple sclerosis (general)
Multi-centre · n=14 · 8 weeks
72% positive (28% good, 44% improved)
Neurosurgical conditions (all)
3-year observational · n=232 · Variable
92% positive; 40% full recovery
Stroke after-effects
Multi-centre · n=11 · 5 weeks
72%
Necrotizing fasciitis
Case series · n=5 · Inpatient
3/5 extremities saved (adjunct to surgery)
Head injury (open brain injury)
Case report · n=1 · 6 weeks
All complaints resolved
Brachial plexus lesion
Case report · n=1 · 5 weeks
Objective improvement; arm circumference +2cm
Cervical disc hernia (tetraparesis)
Case report · n=1 · 6 weeks
Symptom-free; returned to work
Metabolic and Cardiovascular
Hypertension
Multi-centre · n=54 · 6 weeks
83%
Circulatory disorders
Multi-centre · n=67 · 6 weeks
93%
Diabetes mellitus
Multi-centre · n=28 · 7 weeks
75%
Diabetic macular edema
Pilot study · n=5 · Variable
60% improved; compliance-dependent
Heart diseases
Multi-centre · n=22 · 7 weeks
64%
Metabolic disorder
Multi-centre · n=16 · 7 weeks
75%
Sleep, Fatigue and Wellbeing
Sleep disorders
Multi-centre · n=176 · 6 weeks
89%
Fatigue / fatigue syndrome
Multi-centre · n=63 · 6 weeks
94%
General wellbeing
Multi-centre · n=223 · 6 weeks
93%
General pain
Multi-centre · n=32 · 5 weeks
97%
Depression
Multi-centre · n=42 · 6 weeks
90%
Psychological symptoms
General practice · n=16 · Variable
100% improved
Psycho-vegetative disorders
Multi-centre · n=21 · 5 weeks
95%
Ophthalmology
Age-related macular degeneration (AMD)
Case series · n=3 · 6 weeks–3 months
3/3 improved visual acuity
Diabetic macular edema
Pilot study · n=5 · Variable
60% improved; compliance-dependent
Diffuse pigment epitheliopathy
Case report · n=1 · 3 months
Vision restored; detachment resolved
Ear, Nose and Throat
Subjective tinnitus
RCT (double-blind) · n=214 · 8 days
69.5% vs 45.3% placebo; p=0.001
Hyperacusis
Open clinical study · n=27 / 24 ears · ~12 sessions
89% subjective; 100% ears improved; avg 10.83 dB
Immune and Inflammatory
Inflammatory processes
Multi-centre · n=46 · 4 weeks
91%
Weak immune system
Multi-centre · n=16 · 5 weeks
100%
Allergies
Multi-centre · n=23 · 5 weeks
87%
Bronchial asthma
Multi-centre · n=21 · 6 weeks
76%
Rheumatic symptoms
Multi-centre · n=48 · 6 weeks
94%
Other Conditions
Migraines
Multi-centre · n=49 · 6 weeks
90%
Headaches
Multi-centre · n=50 · 5 weeks
92%
Stomach complaints
Multi-centre · n=16 · 4 weeks
94%
Incontinence / urination disorders
Multi-centre · n=10 · 5 weeks
90%
Tinnitus
Multi-centre · n=33 · 6 weeks
76%
Fibromyalgia
Multi-centre · n=12 · 7 weeks
50%
Heart diseases
Multi-centre · n=22 · 7 weeks
64%
Spinal disc complaints
Multi-centre · n=33 · 6 weeks
61%
Honest reading of the data
Not every condition responded equally. The weakest responses in the compendium were fibromyalgia (50%), heart diseases (64%), and spinal disc complaints (61%). BEMER is a microcirculatory support tool — conditions where the primary pathology is structural (disc herniation, advanced heart disease) show lower response rates than conditions where vascular function is the dominant driver. This is consistent with the mechanism and provides a useful guide to where BEMER is most and least likely to produce significant benefit.
About this data
Primary source: BEMER Medical Expert Center Research Compendium, October 2013 (534 pages). Studies span 1999–2013.
Multi-centre data (the largest dataset): AFB Academy for Bioenergetics study — 1,116 patients, 2,031 illness cases, 220 medical facilities across Germany, Austria and Switzerland. Predominantly treatment-resistant cases selected by physicians. Average treatment period: 6 weeks.
Device used: BEMER 3000 (the predecessor to the current BEMER Evo generation). The Evo generation delivers the same patented electromagnetic signal with improved applicator engineering and digital control.
Positive outcome definition: Unless otherwise specified, “positive outcome” combines symptom-free/good and improved results, reported separately in the detailed tables above.